Patent application number | Description | Published |
20090202587 | COMPOSITIONS COMPRISING HMW-MAA AND FRAGMENTS THEREOF, AND METHODS OF USE THEREOF - This invention provides recombinant polypeptides comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA), recombinant | 08-13-2009 |
20110124004 | UTILITY OF HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN IN DIAGNOSIS AND TREATMENT OF CANCER - HMW-MAA antibody cocktails and their uses in detecting cancer and isolating cancer cells are disclosed. Also disclosed are methods of detecting cancer based on the presence of an HMW-MAA genomic sequence in circulating DNA, as well as the increased expression of the HMW-MAA gene and the reduced methylation of the HMW-MAA gene promoter in tissues and circulating cells. | 05-26-2011 |
20110124007 | UTILITY OF HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN IN DIAGNOSIS AND TREATMENT OF CANCER - HMW-MAA antibody cocktails and their uses in detecting cancer and isolating cancer cells are disclosed. Also disclosed are methods of detecting cancer based on the presence of an HMW-MAA genomic sequence in circulating DNA, as well as the increased expression of the HMW-MAA gene and the reduced methylation of the HMW-MAA gene promoter in tissues and circulating cells. | 05-26-2011 |
20110171229 | MONOCLONAL ANTIBODIES FOR CSPG4 FOR THE DIAGNOSIS AND TREATMENT OF BASAL BREAST CARCINOMA - It is disclosed herein that condroitin sulfate proteoglycan 4 (CSPG4), also known as high molecular weight melanoma associated antigen, is overexpressed on basal breast carcinoma cells (BBC), specifically triple negative basal breast carcinoma cells (TNBC). Methods for detecting basal breast cancer in a subject are disclosed. Methods are also disclosed for inhibiting the growth of a basal breast cancer cell. These methods include contacting the basal breast cancer cell with an effective amount of an antibody that specifically binds CSPG4. Additional treatment methods, and the use of antibody panels, are also described herein. | 07-14-2011 |
20110200608 | FULLY HUMAN ANTIBODIES TO HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN AND USES THEREOF - Disclosed herein are isolated human monoclonal antibodies, and functional fragments thereof, that specifically bind HMW-MAA. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect HMW-MAA in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed. | 08-18-2011 |
20120009194 | ANTIBODIES TO ENDOPLASMIN AND THEIR USE - Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma. | 01-12-2012 |
20120148598 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 - Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720. | 06-14-2012 |
Patent application number | Description | Published |
20130259865 | FULLY HUMAN ANTIBODIES TO HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN AND USES THEREOF - Disclosed herein are isolated human monoclonal antibodies, and functional fragments thereof, that specifically bind HMW-MAA. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect HMW-MAA in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed. | 10-03-2013 |
20130259873 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS HMW-MAA - Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds high molecular weight melanoma associated antigen (HMW-MAA), also known as CSPG4; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720. | 10-03-2013 |
20140004124 | MONOCLONAL ANTIBODIES FOR CSPG4 FOR THE DIAGNOSIS AND TREATMENT OF BASAL BREAST CARCINOMA | 01-02-2014 |
20140010811 | ANTIBODIES TO ENDOPLASMIN AND THEIR USE - Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma. | 01-09-2014 |
20140234324 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 - Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720. | 08-21-2014 |
Patent application number | Description | Published |
20090266435 | Grounding system for a heated hose - A sturdy electrical power circuit and grounding circuit for an electrically-heated hose is formed by electrically connecting a grounding wire extending along the length of the hose to a pair of fluid couplings fitted on opposite ends of the hose. The grounding wire is mechanically clamped against the inner wall of the hose by radially-outwardly expanding a tube on each coupling against the grounding wire to secure the grounding wire in place while simultaneously forming an electrical connection between the grounding wire and the fluid couplings. | 10-29-2009 |
20130042938 | GROUNDING SYSTEM FOR A HEATED HOSE - A grounded electrical circuit in a heated hose is provided. In one embodiment, the heated hose assembly includes: a flexible hose body; a first and a second heating wires and a hose ground wire each extending longitudinally and parallel to an axis of the hose body and within an inner wall; a first fluid coupling provided on the first end portion of the flexible hose body, the first fluid coupling comprising a stem inserted into the flexible hose body and radially clamping an end of the hose ground wire against an inner surface of the inner wall, such that a contact between the first fluid coupling and the end of the hose ground wire grounds the hose ground wire; a power cord electrically connected to the first and second heating wires and to the hose ground wire; and a thermostat electrically connected to the first and second heating wires. | 02-21-2013 |
20130091700 | GROUNDING SYSTEM FOR A HEATED HOSE - A method of forming a grounded electrical circuit in a heated hose is provided. In one embodiment, the method includes: positioning a ground wire, a first heating wire, and a second heating wire axially within an inner wall of the hose; removing the end portions of the heated hose, such that end portions of the first heating wire, the second heating wire, and the ground wire are exposed; and positioning a ring around the first end portion of the hose. Exposed end portions of the first and second heating wires are folded to be positioned axially along an outer surface of the hose body. The exposed end portion of the grounding wire is folded radially inward, such that the grounding wire is positioned axially along an inner surface of the inner wall and against the ring. A stem of a first fluid coupling is inserted into the first end portion of the heated hose, such that the stem contacts the exposed end portion of the grounding wire. | 04-18-2013 |